CRO-Based Medical Writing
Where clinical evidence becomes
submission-ready writing.
CRO-Based Medical Writing Company
Research with Purpose. Writing with Precision.
CRO-Based Medical Writing Company
Research with Purpose. Writing with Precision.
Famorcr — Famor Clinical Research Solutions — was launched on 15 July 2026 to give pharmaceutical, biotech and clinical research organisations a dedicated medical writing partner: one that treats every document as both a scientific record and a regulatory instrument.
Scope: Clinical Research, Clinical Trial Management, Pharmacovigilance, Medical Writing, Regulatory Consulting, Data Management, Biostatistics and Allied Healthcare Research Services.
We work across the full regulatory and clinical writing lifecycle — from early protocol drafting through clinical study reports, manuscripts and submission-ready documentation. Every deliverable passes through a structured editorial process: medical accuracy, regulatory compliance, and language precision, checked in that order.
Our writers and reviewers work as an extended, globally distributed team, so client engagements can draw on therapeutic-area expertise and regulatory-region knowledge as each project needs it, without the overhead of a single in-house department.
To deliver scientifically rigorous, regulatory-compliant medical and clinical writing that moves research toward real-world impact — with precision, integrity and consistency at every stage.
To be a globally trusted medical writing partner for pharmaceutical, biotech and CRO organisations — recognised for research-grade quality, ethical rigor and dependable delivery across the clinical and regulatory writing lifecycle.
To become the first-call medical writing partner for companies entering new regulatory markets — pairing therapeutic-area depth with documentation that clears review on the first pass.
A look at the kind of clinical, laboratory and documentation work our engagements are built around.
Every service is delivered against ICH-GCP, GPP3 and journal- or agency-specific formatting standards, with a dedicated reviewer on every document.
Protocols, CSRs, manuscripts, safety and submission documents drafted by subject-matter writers, not generalists.
Independent medical, regulatory and language review on every document before it reaches you.
Every deliverable checked against ICH-GCP, GPP3 and the target region's regulatory format.
Tracked versions, clear turnaround windows and a single point of contact from brief to sign-off.
ICH E3-compliant CSRs, from synopsis to full report, aligned with underlying protocols and statistical outputs.
Study-design protocols, synopses and amendments for Phase I–IV trials, written for site and regulator readiness.
CTD/eCTD modules, IND/NDA/BLA documentation and agency-response writing for global regulatory filings.
Journal-ready manuscripts, abstracts and posters written to GPP3 and target-journal guidelines.
PSURs, DSURs, case narratives and aggregate safety reports prepared to global PV reporting standards.
Living IBs kept current with emerging safety and efficacy data across the life of a trial.
Plain-language ICFs and patient-facing documents that stay compliant without losing clarity.
PRISMA-aligned literature reviews and evidence synthesis for publication or submission support.
Standard operating procedures and quality-system documents built for audit readiness.
The same five stages run on every engagement, regardless of document type — so quality doesn't depend on which writer picks up the brief.
Requirements, therapeutic area, target regulator or journal, and timelines confirmed before any drafting starts.
Matched to writers and reviewers with the relevant therapeutic-area and regulatory-region experience.
Structured writing against source data, protocol and the applicable regulatory or journal guidance.
Independent review for medical accuracy, compliance and internal consistency before it reaches you.
Tracked-changes delivery, a defined revision window, and sign-off with a single point of contact.
Protocol work is where a trial's scientific and regulatory logic is set — our process keeps that logic traceable through every revision.
Phase I–IV clinical trial protocols built from objectives and endpoints through to full ICH M11-aligned study documents.
SAP drafting and cross-checking against protocol endpoints, so analysis and design stay aligned.
Version-controlled amendment writing with clear rationale and impact assessment for each change.
Independent review of draft protocols against ICH-GCP and region-specific regulatory expectations.
Formatting and language adaptation so protocols are ready for multi-site and multi-region rollout.
We operate as a focused medical writing practice, not a multi-layered agency — so engagement budgets go toward the writers and reviewers actually working on your documents, not toward extra management layers.
That structure keeps our pricing competitive against larger CROs and standalone writing agencies, without cutting corners on ICH-GCP rigor, review depth, or turnaround discipline.
No layered account-management overhead — budget is spent on writing and review, not process.
You work directly with the writer and reviewer on your document, not a relay of account managers.
Quoted per document or engagement upfront, so costs are clear before drafting begins.
Engagements are staffed against therapeutic area and regulatory region, drawing on an extended network of medical writers, regulatory specialists and reviewers.